Skip to content

US · CODX · BIOTECHNOLOGY

Co-Diagnostics, Inc. (CODX) intrinsic value and stock valuation

$0.13as of 2026-11-21 · Mkt cap 1.69M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Co-Diagnostics, Inc. DCF and intrinsic value

InvestorsCraft values CODX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CODX’s statements →

Co-Diagnostics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Salt Lake City, UT 84109 co-dx.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$620K-61.6% 5y CAGRd
20142025
Net income
-$-46.9M
20142025
Free cash flow
-$-29.84M
20142025
Total equity
$20.6M-20.9% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$620K$3.92M$6.81M$34.2M$97.9M
Operating income-$-31.28M-$-40.08M-$-42.71M-$-26.98M$46.1M
Net income-$-46.9M-$-37.64M-$-35.33M-$-14.24M$36.7M
EPSd-$-35.26M-$-37.27M-$-36.05M-$-13.56M$36.7M
Operating cash flow-$-29.14M-$-29.16M-$-22.08M$6.57M$41.1M
Capital expenditure-$-700K-$-750K-$-1.37M-$-1.43M-$-670K
Free cash flow-$-29.84M-$-29.9M-$-23.45M$5.14M$40.4M
Total assets$24.7M$64M$95.3M$123.1M$160M
Total debt$1.24M$2.15M$2.99M$350K$0.00
Net debt-$-10.65M-$-780K-$-11.93M-$-22.63M-$-88.61M
Total equity$20.6M$54.3M$86M$114.5M$134.5M
Cash and short-term investments$11.9M$29.8M$58.6M$81.3M$89.9M
Income statement
20252024202320222021
Revenue$620K$3.92M$6.81M$34.2M$97.9M
Cost of revenue$220K$1M$4.18M$5.48M$11.6M
Gross profit$400K$2.92M$2.63M$28.7M$86.3M
Research and development expenses$19.1M$21M$23M$17.4M$15M
Selling, general and administrative expenses$11.4M$20.6M$21.1M$21.6M$25M
Other expenses$1.11M$1.38M$1.23M$16.7M$340K
Operating expenses$31.7M$43M$45.3M$55.7M$40.3M
Cost and expenses$31.9M$44M$49.5M$61.2M$51.8M
Interest income$290K$1.09M$1.16M$700K$50K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.11M$1.38M$1.23M$1.28M$340K
Ebitda-$-47.41M-$-36.2M-$-36.88M-$-10.31M$46M
Operating income-$-31.28M-$-40.08M-$-42.71M-$-26.98M$46.1M
Total other income/expenses, net-$-17.23M$2.5M$4.6M$8.13M-$-430K
Income before tax-$-48.51M-$-37.58M-$-38.11M-$-18.85M$45.6M
Income tax expense-$-1.62M$60K-$-2.78M-$-4.61M$8.98M
Net income-$-46.9M-$-37.64M-$-35.33M-$-14.24M$36.7M
Weighted average shares outstanding$1.33M$1.01M$980K$1.05M$960K
Weighted average diluted shares outstanding$1.33M$1.01M$980K$1.05M$1M
Balance sheet
20252024202320222021
Cash and short-term investments$11.9M$29.8M$58.6M$81.3M$89.9M
Net receivables$190K$130K$330K$5.4M$20.9M
Inventory$990K$1.07M$1.66M$5.31M$2M
Total current assets$13.7M$32.3M$62.1M$92.7M$115.1M
Property, plant and equipment, net$3.48M$4.88M$6M$2.91M$1.93M
Goodwill and intangible assets$7.22M$26.1M$26.4M$26.8M$41.9M
Long-term investments$350K$730K$770K$670K$1M
Total non-current assets$11.1M$31.7M$33.2M$30.4M$44.9M
Total assets$24.7M$64M$95.3M$123.1M$160M
Accounts payable$1.88M$3.29M$1.48M$950K$610K
Short-term debt$660K$920K$840K$300K$0.00
Deferred revenue$10K$0.00$360K$0.00$150K
Total current liabilities$3.54M$7.32M$5.75M$3.87M$12.6M
Long-term debt$570K$1.24M$2.15M$50K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$570K$2.37M$3.56M$4.69M$13M
Capital lease obligations$660K$2.15M$2.99M$350K$0.00
Total liabilities$4.11M$9.69M$9.31M$8.57M$25.6M
Common stock$70K$40K$40K$30K$30K
Retained earnings-$-80.37M-$-33.04M$4.6M$39.9M$54.2M
Accumulated other comprehensive income (loss)-$0.00$420K$150K$290K$0.00
Total equity$20.6M$54.3M$86M$114.5M$134.5M
Total investments$350K$27.5M$44.4M$59M$2.26M
Total debt$1.24M$2.15M$2.99M$350K$0.00
Net debt-$-10.65M-$-780K-$-11.93M-$-22.63M-$-88.61M
Cash flow statement
20252024202320222021
Net income-$-46.9M-$-37.64M-$-35.33M-$-14.24M$36.7M
Depreciation and amortization$1.11M$1.38M$1.23M$1.28M$340K
Stock-based compensation$2.25M$5.43M$8.34M$7.54M$5.51M
Change in working capital-$-3.17M$2.75M$5.64M$6.19M-$-2.9M
Accounts receivable-$-30K$190K$2.54M$14.9M-$-8.74M
Inventory$130K$270K$410K-$-3.67M$5.71M
Accounts payable-$-3.11M$2.16M$1.77M-$-2.48M-$-300K
Net cash provided by operating activities-$-29.14M-$-29.16M-$-22.08M$6.57M$41.1M
Investments in property, plant and equipment-$-700K-$-750K-$-1.37M-$-1.43M-$-670K
Acquisitions, net-$-100K-$-140K$0.00$0.00$1.69M
Net cash used for investing activities$26.3M$17.1M$15.4M-$-58.17M$4.1M
Common stock issued$11.8M$100K$0.00$0.00$450K
Common stock repurchased$0.00$0.00-$-1.36M-$-14.21M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.8M$100K-$-1.36M-$-14.03M$450K
Net change in cash$8.95M-$-11.98M-$-8.06M-$-65.63M$45.6M
Cash at end of period$11.9M$2.94M$14.9M$23M$88.6M
Operating cash flow-$-29.14M-$-29.16M-$-22.08M$6.57M$41.1M
Capital expenditure-$-700K-$-750K-$-1.37M-$-1.43M-$-670K
Free cash flow-$-29.84M-$-29.9M-$-23.45M$5.14M$40.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Co-Diagnostics, Inc.

        Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

        CEO
        Dwight Egan
        Employees
        115
        Beta
        2.85

        Explore

        Frequently asked questions

        What is the intrinsic value of Co-Diagnostics, Inc. (CODX)?

        Co-Diagnostics, Inc. (CODX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CODX undervalued?

        CODX trades at a price of $0.13 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.